Pooled secondary analysis of phase 3 REMIX-1/2 in adults with chronic spontaneous urticaria despite H1-antihistamines: remibrutinib (n=606) vs placebo (n=306) improved activity score (−11.8 vs −3.6) and sleep within 1 week, sustained to week 52.
Secondary analysisn = 912
Mosnaim et al. Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2